Philippines - English - FDA (Food And Drug Administration)

farmline agriventures, inc.; distributor: farmline agriventures, inc. - live attenuated fowl pox (fp) virus vaccine (vet.) - freeze-dried powder for injection (wing web) - formulation: each 0.012 ml (dose) contains: fowl pox virus (brescia p1 strain) tcid - tissue culture infectious dose

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - clindamycin hydrochloride -

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - clindamycin palmitate hydrochloride (unii: vn9a8jm7m7) (clindamycin - unii:3u02el437c) - clindamycin 75 mg in 5 ml - cleocin pediatric (clindamycin palmitate hcl) is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of colitis, as described in the boxed warning , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and

United States - English - NLM (National Library of Medicine)

medical purchasing solutions, llc - clindamycin phosphate (unii: eh6d7113i8) (clindamycin - unii:3u02el437c) - cleocin phosphate products are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. cleocin phosphate products are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of antibiotic-associated pseudomembranous colitis, as described in the boxed warning , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. indicated surgical procedures should be performed in conjunction with antibiotic therapy. cleocin phosphate is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, streptococcus pneumoniae, other streptococci (except e. faecalis ), and staphylococcus aureus. skin and skin structure infections caused by streptococcus pyogenes, staphylococcus aureus , and anaerobes. gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. septicemia caused by staphylococcus aureus , streptococci (except enterococcus faecalis ), and susceptible anaerobes. bone and joint infections including acute hematogenous osteomyelitis caused by staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. to reduce the development of drug-resistant bacteria and maintain the effectiveness of cleocin phosphate and other antibacterial drugs, cleocin phosphate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. this drug is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.

Malta - English - Medicines Authority

crescent pharma international limited 260, triq san albert, gzira gzr 1150, malta - atenolol - tablet - atenolol 25 mg - beta blocking agents

Malta - English - Medicines Authority

crescent pharma international limited 260, triq san albert, gzira gzr 1150, malta - atenolol - tablet - atenolol 50 mg - beta blocking agents

Malta - English - Medicines Authority

crescent pharma international limited 260, triq san albert, gzira gzr 1150, malta - atenolol - tablet - atenolol 100 mg - beta blocking agents

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - clindamycin phosphate (unii: eh6d7113i8) (clindamycin - unii:3u02el437c) - clindamycin 20 mg in 1 g - cleocin vaginal cream 2%, is indicated in the treatment of bacterial vaginosis (formerly referred to as haemophilus vaginitis, gardnerella vaginitis, nonspecific vaginitis, corynebacterium vaginitis, or anaerobic vaginosis). cleocin vaginal cream 2%, can be used to treat non-pregnant women and pregnant women during the second and third trimester. (see clinical studies.) note : for purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a ph of greater than 4.5, (b) emits a "fishy" amine odor when mixed with a 10% koh solution, and (c) contains clue cells on microscopic examination. gram's stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent lactobacillus morphology, (b) predominance of gardnerella morphotype, and (c) absent or few white blood cells. other pathogens commonly associated with vulvovaginitis, eg, trichomonas vaginalis, chlamydia trachomatis, n

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - clindamycin phosphate (unii: eh6d7113i8) (clindamycin - unii:3u02el437c) - cleocin vaginal ovules are indicated for 3-day treatment of bacterial vaginosis in non-pregnant women. there are no adequate and well-controlled studies of cleocin vaginal ovules in pregnant women. note: for purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a ph of greater than 4.5, (b) emits a "fishy" amine odor when mixed with a 10% koh solution, and (c) contains clue cells on microscopic examination. gram's stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent lactobacillus morphology, (b) predominance of gardnerella morphotype, and (c) absent or few white blood cells. other pathogens commonly associated with vulvovaginitis, e.g., trichomonas vaginalis , chlamydia trachomatis , neisseria gonorrhoeae , candida albicans , and herpes simplex virus, should be ruled out. cleocin vaginal ovules are contraindicated in individuals with a history of hypersensitivity to clindamycin, lincomycin, or any of the components of this vaginal suppository. cleocin vaginal ovules are also contraindicated in individuals with a history of regional enteritis, ulcerative colitis, or a history of "antibiotic-associated" colitis.

United States - English - NLM (National Library of Medicine)

u.s. pharmaceuticals - clindamycin phosphate (unii: eh6d7113i8) (clindamycin - unii:3u02el437c) - cleocin vaginal ovules are indicated for 3-day treatment of bacterial vaginosis in non-pregnant women. there are no adequate and well-controlled studies of cleocin vaginal ovules in pregnant women. note : for purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a ph of greater than 4.5, (b) emits a "fishy" amine odor when mixed with a 10% koh solution, and (c) contains clue cells on microscopic examination. gram's stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent lactobacillus morphology, (b) predominance of gardnerella morphotype, and (c) absent or few white blood cells. other pathogens commonly associated with vulvovaginitis, eg, trichomonas vaginalis , chlamydia trachomatis , neisseria gonorrhoeae , candida albicans , and herpes simplex virus, should be ruled out. cleocin vaginal ovules are contraindicated in individuals with a history of hypersensit